

WHAT IS CLAIMED IS:

1. Use of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and a blood reduction agent for manufacturing a medicament for the treatment of diabetes mellitus, wherein the blood reduction agent is biguanide, or α -glycosidase inhibitor.
5
2. The use of claim 1, wherein the (R)-(+)-verapamil or the pharmaceutically acceptable salt thereof is in crystalline form.
3. The use of claim 2, wherein the (R)-(+)-verapamil exist in its hydrochloride salt.
- 10 4. The use of claim 1, wherein the biguanide is metformin, phenformin, or buformin.
5. The use of claim 1, wherein the α -glycosidase inhibitor is acarbose, miglitol, or voglibose.
6. The use of claim 1, wherein the medicament is suitable for oral,
15 intravenous, intramuscular, subcutaneous, transmucosal, or intrarectal administration.
7. The use of claim 6, wherein the medicament for oral administration is provided as tablets, pills, granules, powders, solutions, suspensions, syrups or capsules.
- 20 8. The use of claim 6, wherein the medicament is to be administered in the amount of 15 to 1,000 mg/day.
9. The use of claim 8, wherein the medicament is to be administered in the amount of 25 to 800 mg/day.